Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct;29(10):1195-1203.
doi: 10.1111/iju.14976. Epub 2022 Jul 20.

Real-world treatment patterns and oncological outcomes in early relapse and refractory disease after bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer

Yasukiyo Murakami  1 , Kazumasa Matsumoto  1 , Makito Miyake  2 , Noriyuki Amano  1 , Soichiro Shimura  1 , Nobutaka Nishimura  2 , Kota Iida  2 , Yuto Matsushita  3 , Takashige Abe  4 , Takeshi Yamada  5 , Motohide Uemura  6 , Yoshiyuki Matsui  7 , Rikiya Taoka  8 , Takahiro Kojima  9 , Takashi Kobayashi  10 , Naotaka Nishiyama  11 , Hiroshi Kitamura  11 , Hiroyuki Nishiyama  12 , Kiyohide Fujimoto  2 , Masatsugu Iwamura  1
Affiliations

Real-world treatment patterns and oncological outcomes in early relapse and refractory disease after bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer

Yasukiyo Murakami et al. Int J Urol. 2022 Oct.

Abstract

Objective: To assess real-world oncological outcomes between the radical cystectomy (RC) group and non-RC group for early relapse and refractory disease.

Methods: We retrospectively analyzed 953 patients with recurrent non-muscle-invasive bladder cancer (NMIBC) who received bacillus Calmette-Guérin (BCG) at 31 affiliated hospitals from 2000 to 2019. Patients with missing data on the timing of failure were excluded and 871 patients remained eligible, of whom 447, 357, and 67 were classified as early relapse/refractory disease, intermediate/late relapse disease, and intolerant disease, respectively. For early relapse/refractory disease, patients were divided into two salvage treatment groups: RC and non-RC. The clinicopathological variables of each group were examined using Kaplan-Meier plots and proportional Cox hazard ratios with matched score analyses to compare oncological outcomes between the two groups.

Results: Significantly worse progression-free survival and cancer-specific survival (CSS) were confirmed in the early relapse/refractory disease group compared to the intermediate/late relapse group. Of the 88 salvage patients in the RC group with early relapse/refractory disease, ≤pT1 was observed in 47, pT2 in 11, and ≥pT3 in 28 (two patients with unknown pT category). In early relapse/refractory disease, the RC group showed significantly high-risk tumor compared to the non-RC group. However, no significant difference was observed in CSS after matched score analyses (p = 0.45) between the RC and non-RC groups.

Conclusions: This study found that the RC group showed no significant superiority compared to the non-RC group in CSS for early relapse/refractory disease in terms of first salvage therapy.

Keywords: Bacillus Calmette-Guérin; early radical cystectomy; salvage treatment.

PubMed Disclaimer

Comment in

References

REFERENCES

    1. Slyvester RJ, van der Meijiden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466-75.
    1. Slyvester RJ, van der Meijiden AP, Witjes JA, Kurth K. Bacillus Calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: meta-analysis pf the published results of randomized clinical trials. J Uro. 2005;174:86-92.
    1. Cookson MS, Herr HW, Zhang Z-F, Soloway S, Sogani PC, Pair WR. The treated natural history of high risk superficial bladder cancer:15 year outcome. J Urol. 1997;158:62-7.
    1. Weizer AZ, Tallman C, Montgomery JS. Lonh term outcomes of intravesial therapy for muscle invasive bladder cancer. World J Urol. 2011;29:59-71.
    1. Matsumoto K, Kikuchi E, Shirakawa H, Hayakawa N, Tanaka N, Ninomiya A, et al. Risk of subsequent tumour recurrence and stage progression in bacilli-Calmette-Guerin relapsing non- muscle invasive bladder cancer. BJU Int. 2012;110(11 Pt B):E508-13.

LinkOut - more resources